Eli Lilly & Co. (LLY): Cancer Breakthrough Could Mean Big Gains for This Pharma Giant

Page 1 of 2

The battle against cancer is both valiant and frustrating. Medical researchers are constantly developing new drugs and treatment methods to fight the dreaded disease, and while most improvements come gradually, the really big progressive leaps in treatment are few and far between.

Pharmaceutical giant Eli Lilly & Co. (NYSE:LLY) announced today what it suspects could be one of those big leaps forward in the battle against one of the most prolific and pernicious varieties of the disease — lung cancer.

In a press release, Eli Lilly & Co. (NYSE:LLY) announced impressive clinical trial results for SQUIRE, the company’s recently completed Phase III clinical study. The study found that “patients with stage IV metastatic squamous non-small cell lung cancer experienced increased overall survival when administered necitumumab in combination with gemcitabine and cisplatin as a first-line treatment, as compared to chemotherapy alone.”

A positive result in a Phase III study, which is one of the critical hurdles before a drug is approved, is a big reason for optimism in patients afflicted with this variety of lung cancer. It’s also a big positive for Lilly, as the mass adoption of an effective new therapy means millions in revenue for many years down the line.

Certainly, traders viewed the news as a big positive, as Eli Lilly & Co. (NYSE:LLY) shares spiked 4.4% in pre-market trade before giving back some of those initial gains.

This news comes at the right time for Lilly, as the company is facing the patent expiration of several of its most profitable drugs, including its best-selling drug, antidepressant Cymbalta. Patent expiration on Cymbalta happens later this year, and that will undoubtedly result in much less revenue from the product in 2014.

As for necitumumab, the therapy still faces regulatory challenges, although nothing more than the usual approval process. The company plans to submit necitumumab to regulators for approval before the end of 2014, and while that may seem like a long time from now, in drug approval terms it’s just around the corner.

Interestingly, the thing that got Wall Street excited about the Lilly announcement on Tuesday was its unexpectedness. ISI Group analyst Mark Schoenebaum, who covers the stock, reflected on the analyst community’s surprise over the news.

In an email note to clients, Schoenebaum wrote, “This is a clear upside surprise, as consensus (and my) expectations for this drug were basically zero.” He added, “Recall that Bristol-Myers Squibb actually RETURNED this drug to Eli Lilly & Co. (NYSE:LLY) in a tacit declaration of no confidence a few years ago.”

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Countries with the Highest Suicide Rates

The 10 Most Technologically Advanced Countries in the World

The 10 Safest Countries in the World to Live in Peace

The 10 Top Selling Smartphones in the World 2014

The 12 Biggest Shopping Centers in the World

The 10 Friendliest Countries in the World

Qihoo 360 Technology Co Ltd (QIHU), Actavis plc (ACT), Yahoo! Inc. (YHOO) Among 20 Long Ideas from Sohn Canada

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!